Welcome to our dedicated page for AGTC news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on AGTC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AGTC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AGTC's position in the market.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) will release 12-month data from its Phase 1/2 clinical trial for X-linked Retinitis Pigmentosa (XLRP) on November 11, 2020. The data will evaluate the durability of effect and safety across multiple patient groups. A conference call will be held at 8:00 AM ET on the same day to discuss the findings. AGTC is focused on developing gene therapies for rare diseases, with active clinical trials for XLRP and other conditions, aiming to address significant unmet clinical needs.
Applied Genetic Technologies Corporation (AGTC), a biotech company focused on gene therapies for rare diseases, announced participation in the Cantor Fitzgerald virtual panel on October 28, 2020, at 10:00 a.m. ET. CEO Sue Washer and VP Dave Knop will discuss key elements of gene therapy manufacturing and AGTC's proprietary processes. The panel will highlight company catalysts over the next year. AGTC is advancing clinical programs for inherited retinal diseases, leveraging its AAV technology for unmet clinical needs in various disorders.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has announced its participation in two upcoming virtual conferences in October 2020. The first is the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa, occurring from October 12-16, where CEO Sue Washer will present on-demand. The second event is the Dry AMD Therapeutic Development Summit on October 28-29, featuring CSO Mark Shearman in a panel discussion on dry AMD patient treatment. AGTC focuses on gene therapies for rare diseases, with clinical trials for inherited retinal diseases.
AGTC has joined the My Retina Tracker® Program as a scientific collaborator, enhancing its development of gene therapies for inherited retinal diseases. This partnership provides AGTC access to deidentified genetic data to identify candidates for clinical trials, focusing on X-linked retinitis pigmentosa (XLRP). AGTC's Phase 1/2 trial is expanding, with a Phase 2/3 trial planned for early 2021. The My Retina Tracker Program, in collaboration with Blueprint Genetics and the Foundation Fighting Blindness, offers no-cost genetic testing and counseling to affected individuals.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced its participation in three upcoming virtual conferences focused on biotechnology. The events include the Wells Fargo Virtual Healthcare Conference on September 10, 2020, where CEO Sue Washer will engage in a fireside chat, and the H.C. Wainwright Global Investment Virtual Conference from September 14-16, 2020, featuring investor meetings. Additionally, AGTC will participate in the Cantor Fitzgerald Global Healthcare Conference on September 16, 2020. Live audio webcasts of the presentations will be available online.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced the publication of preclinical data validating its gene therapy transgene (hRPGRco) for treating X-linked retinitis pigmentosa (XLRP). The study demonstrated that hRPGRco exhibited stronger expression and broader therapeutic index than alternative transgenes in a canine model, supporting its use in the ongoing Phase 1/2 clinical trial. AGTC plans to initiate a Phase 2/3 trial for the gene therapy in Q1 2021, with over 100 patients currently enrolled in clinical trials, showing favorable safety profiles.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced the formation of a Patient Advisory Council aimed at enhancing its patient-centric culture in clinical and pre-clinical programs. The council, led by Jill Dolgin, PharmD, includes advocates from the inherited retinal diseases community focusing on X-linked retinitis pigmentosa (XLRP). AGTC is also expanding its ongoing Phase 1/2 clinical trial and preparing for a Phase 2/3 trial expected to start in Q1 2021, following FDA feedback, to collect functional data on its gene therapy candidate.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced its inclusion in the Russell 3000® and 2000® Indexes, effective June 29, 2020. This addition reflects the company's advancements in gene therapies for rare diseases, particularly ongoing clinical programs like X-linked retinitis pigmentosa and achromatopsia. AGTC's CEO emphasized the boost in visibility and institutional interest resulting from the inclusion. Russell indexes manage approximately $9 trillion in assets, serving as benchmarks for investments, enhancing exposure for AGTC among investors.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has announced advancements in its manufacturing process for clinical trial materials, particularly for X-linked retinitis pigmentosa (XLRP). Improvements in their proprietary HSV-based process have resulted in AAV vector quality exceeding 90% full capsids and over 97% purity levels. Yields have increased more than tenfold compared to previous campaigns, allowing significant reductions in production costs. These advancements position AGTC to meet larger market demands and support future growth in gene therapy initiatives.
Applied Genetic Technologies Corporation (AGTC), a biotechnology firm focused on gene therapies for rare diseases, announced that CEO Sue Washer will present at the BMO Capital Markets 2020 Healthcare Conference on June 23 at 10:30 am ET. The event can be streamed live on the company's website, with a replay available afterward. Earlier this year, AGTC reported promising interim data from its clinical trials for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) therapies, demonstrating the company's commitment to addressing significant unmet medical needs.
